These observations suggest that SOCS1-KIR treatment triggers changes in lymphocyte dynamics, hinting at the therapeutic potential of peptide administration for alleviating SLE-related pathology (193) (Figure 6). The gene discussed is SOCS1; the disease is systemic lupus erythematosus.